【摘要】 本研究提高对尼洛替尼治疗伊马替尼耐药伴V299L突变的慢性髓系白血病(chronic myeloid leukemia,CML)患者的临床认识。收集我院2例伴V299L突变的CML患者尼洛替尼治疗前后的骨髓标本,采用巢式PCR扩增并测序的方法检测ABL突变,分析临床特征。结果表明,2例伊马替尼耐药的CML患者均发生V299L突变,1例经尼洛替尼治疗6个月后V299L突变转为阴性,并取得完全血液学缓解;另1例经尼洛替尼治疗7个月后V299L突变转为阴性,并取得明显分子学缓解。结论:尼洛替尼治疗伊马替尼耐药伴V299L突变的CML患者安全性和疗效令人满意。更多还原

【Abstract】 This study was aimed to enhance clinical understanding the effect of nilotinib on CML patients with V299L mutation who were resistant to imatinib. Bone marrow specimens from 2 cases of CML with V299L mutation were collected before and after the treatment with nilotinib. ABL mutation was detected by nested reverse transcription polymerase chain reaction( PCR) followed by direct sequencing. The clinical characteristics of the two cases were analyzed. The results showed that both cases were resistant to imatinib presented V299L mutation. Out of them 1 case achieved complete haematological response( CHR) after treatment with nilotinib for 6 months and another case abtained obvious molecular response after using nilotinib for 7 month. V299L mutation of both cases was turned into negative after the treatment with nilotinib. It is concluded that the nilotinib can safely and effectively override tyrosine kinase inhibitor( TKI) resistance mediated by the V299L mutation. The safety and efficacy of nilotinib for treatment of CML patients with TKI resistance and V299L mutation are satisfactory.更多还原